FLT3 and acute myeloid leukemia: Triple therapy combining venetoclax, decitabine and an FLT3 inhibitor achieved CR/CRi in 92% in a small cohort of newly diagnosed AML patients [134] compared to the aforementioned 33–72% response rates with the combination of venetoclax and decitabine (Table 3) [31,37,38,39,40,41].